IRIS
CANONICA, Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.017
AS - Asia 9.573
SA - Sud America 5.867
EU - Europa 3.971
AF - Africa 895
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 17
AN - Antartide 1
Totale 37.366
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.590
SG - Singapore 4.996
BR - Brasile 4.835
VN - Vietnam 1.822
CN - Cina 1.344
FI - Finlandia 969
IE - Irlanda 838
NG - Nigeria 601
AR - Argentina 432
FR - Francia 422
DE - Germania 401
GB - Regno Unito 281
NL - Olanda 272
CA - Canada 236
TR - Turchia 220
EC - Ecuador 214
ID - Indonesia 193
RU - Federazione Russa 180
IT - Italia 176
BD - Bangladesh 159
HK - Hong Kong 154
IN - India 121
CO - Colombia 119
MX - Messico 118
SE - Svezia 116
ZA - Sudafrica 99
IL - Israele 94
PY - Paraguay 83
IQ - Iraq 81
UA - Ucraina 74
CL - Cile 53
PK - Pakistan 52
UZ - Uzbekistan 48
VE - Venezuela 48
ES - Italia 35
MA - Marocco 35
EG - Egitto 33
JP - Giappone 33
PL - Polonia 33
SA - Arabia Saudita 33
UY - Uruguay 33
KE - Kenya 32
PE - Perù 32
TN - Tunisia 30
BE - Belgio 27
DZ - Algeria 26
KR - Corea 25
AZ - Azerbaigian 21
DO - Repubblica Dominicana 20
CZ - Repubblica Ceca 19
NP - Nepal 19
RO - Romania 19
AU - Australia 18
IR - Iran 18
AE - Emirati Arabi Uniti 16
BO - Bolivia 16
KZ - Kazakistan 16
AT - Austria 15
TT - Trinidad e Tobago 14
JO - Giordania 12
KG - Kirghizistan 12
AL - Albania 10
LT - Lituania 10
OM - Oman 10
BG - Bulgaria 9
ET - Etiopia 9
A2 - ???statistics.table.value.countryCode.A2??? 8
AM - Armenia 8
GE - Georgia 8
SN - Senegal 8
HN - Honduras 7
KW - Kuwait 7
PA - Panama 7
BA - Bosnia-Erzegovina 6
DK - Danimarca 6
GR - Grecia 6
LB - Libano 6
PH - Filippine 6
PT - Portogallo 6
AO - Angola 5
BW - Botswana 5
GA - Gabon 5
MY - Malesia 5
NO - Norvegia 5
PR - Porto Rico 5
PS - Palestinian Territory 5
RS - Serbia 5
SY - Repubblica araba siriana 5
TW - Taiwan 5
BH - Bahrain 4
BY - Bielorussia 4
CH - Svizzera 4
CI - Costa d'Avorio 4
CR - Costa Rica 4
EU - Europa 4
HU - Ungheria 4
MD - Moldavia 4
MN - Mongolia 4
NZ - Nuova Zelanda 4
SV - El Salvador 4
Totale 37.314
Salva come PNG Salva come JPEG
Città #
Wilmington 4.542
San Mateo 1.699
The Dalles 1.514
Singapore 1.400
Dallas 1.079
Ann Arbor 1.032
Shanghai 1.004
Helsinki 966
Leawood 869
Dublin 833
Lawrence 773
Princeton 773
Ho Chi Minh City 707
Benin City 596
Fairfield 577
Woodbridge 513
Chandler 488
São Paulo 396
Paris 392
Hanoi 354
Ashburn 282
Amsterdam 243
Beijing 199
London 184
Kocaeli 169
New York 169
Toronto 165
Hong Kong 143
Rio de Janeiro 140
Boardman 109
Norwalk 96
Brasília 86
Santa Clara 86
Curitiba 85
Los Angeles 85
Belo Horizonte 83
Guayaquil 83
Haiphong 76
Porto Alegre 74
Campinas 62
Guarulhos 61
Da Nang 60
Biên Hòa 59
Quito 53
Salvador 50
Tashkent 45
Dhaka 43
Monmouth Junction 43
Moscow 41
Hải Dương 39
Phoenix 39
Seattle 38
Buenos Aires 36
Jakarta 36
Ribeirão Preto 36
Asunción 35
Sorocaba 35
Goiânia 34
Falkenstein 32
Fortaleza 31
Johannesburg 31
Milan 31
São Bernardo do Campo 31
Ninh Bình 30
Thái Nguyên 30
Manaus 29
Montevideo 29
Recife 29
Thái Bình 29
Bogotá 27
Phủ Lý 27
Caxias do Sul 26
Santo André 26
Ha Long 25
Juiz de Fora 25
Medellín 25
Nova Iguaçu 25
Cape Town 24
Des Moines 24
Lấp Vò 24
Nairobi 24
Orem 24
Piracicaba 24
Warsaw 24
Baghdad 23
Betim 23
Can Tho 23
Brooklyn 22
Brussels 21
Montreal 21
Osasco 21
Santiago 21
Tokyo 21
Volta Redonda 21
Duque de Caxias 20
Florianópolis 20
Houston 20
Reston 20
Uberlândia 20
Baku 19
Totale 24.951
Salva come PNG Salva come JPEG
Nome #
100 years of immunotherapy: the Monaco charter. under the high patronage of His Serene Highness Prince Albert II of Monaco 615
Quality of life and polysensitization in young men with intermittent asthma 204
A critical appraisal on AIT in childhood asthma. 126
Very rapid improvement of extended nitric oxide parameters, associated with clinical and functional betterment, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with Dupilumab 119
Effects on symptoms and quality of life of hypertonic saline nasal spray added to antihistamine in persistent allergic rhinitis--a randomized controlled study 116
Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry 107
Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study. 107
An academic allergy unit during COVID-19 pandemic in Italy. 102
Omalizumab for Idiopathic Nonhistaminergic Angioedema: Evidence for Efficacy in 2 Patients. 98
A Charter to Improve Patient Care in Severe Asthma 93
Comparison of the colony forming capacities of human T lymphocyte subpopulations 92
Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis 88
Pidotimod: The state of art 87
60Co therapy as an "allergic breakthrough" in a case of food allergy 87
2019 ARIA Care pathways for allergen immunotherapy 85
Evolving phenotypes to endotypes: is precision medicine achievable in asthma? 84
Pitfalls in respiratory allergy management: alexithymia and its impact on patient-reported outcomes 83
30 Years Of Sublingual Immunotherapy 83
A 4-year trial of tiotropium in chronic obstructive pulmonary disease 82
Aligning the Good Practice MASK With the Objectives of the European Innovation Partnership on Active and Healthy Ageing 81
A multi-allergen ELISA screening method. Comparison with Pharmacia CAP system and Phazet skin prick test 81
A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy 79
Immunological mechanisms underlying chronic rhinosinusitis with nasal polyps 76
A model of allergen-driven human airway contraction:beta2 pathway dysfunction without cytokine involvement 75
A double-blind, placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects 75
Pharmacoeconomic evaluation of oral corticosteroid adverse events in patients with severe asthma 75
Strategies to reduce corticosteroid-related adverse events in asthma 74
The Severe Asthma Network in Italy: Findings and Perspectives 73
A multicentric study on sensitivity and specificity of a new in vitro test for measurement of IgE antibodies 73
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis 73
Treatable traits in chronic rhinosinusitis with nasal polyps 73
Microarray Immunodiagnostics for Aeroallergens 72
Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients 72
A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress 71
A survey of the burden of allergic rhinitis in Europe 71
Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions 70
Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment 69
Turkish Version of the Chronic Urticaria Quality of Life Questionnaire: Cultural Adaptation, Assessment of Reliability and Validity 69
Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study 69
360 degree perspective on allergic rhinitis management in Italy: A survey of GPs, pharmacists and patients 68
A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL) 68
Real-life studies of biologics used in asthma patients: key differences and similarities to trials 67
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy 67
[GA(2)LEN (Global Allergy and Asthma European Network): European network of excellence for asthma and allergic diseases] 67
Pilot study of mobile phone technology in allergic rhinitis in European countries: The MASK-rhinitis study 67
Appropriateness in allergic respiratory diseases health care in Italy: definitions and organizational aspects 66
[Our experience in the treatment of bronchial asthma and asthmatic bronchitis with salbutamol] 66
Performance evaluation of ImmunoCAP® ISAC 112: a multi-site study 65
World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Prebiotics 64
Assessing biomarkers in a real-world severe asthma study (ARIETTA) 64
EAACI/GA2LEN/EDF guideline: management of urticaria 64
Choosing wisely in Allergology: a Slow Medicine approach to the discipline promoted by the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC) 64
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials 64
Escaping the trap of allergic rhinitis. 63
EAACI guidelines on allergen immunotherapy: Executive statement 63
EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria 63
[ICAM-1 and allergic inflammation] 63
Efficacy and Safety of High ICS Dose Fixed-Combination ICS/LABA/LAMA pMDI Compared with ICS/LABA and ICS/LABA plus LAMA in Patients with Uncontrolled Asthma: The TRIGGER Study 62
Suppressor activity of T cells bearing Fc-receptors for IgG on lymphoid colony formation 62
GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe 62
Current insights in allergen immunotherapy. 61
Diagnosis and management of moderate to severe adult atopic dermatitis: a Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), and the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA) 61
Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone 61
New drugs in early-stage clinical trials for allergic rhinitis 60
EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria 60
Work productivity in rhinitis using cell phones: The MASK pilot study 60
Asthma: personalized and precision medicine 59
The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update 59
A Review of the Evidence from Comparative Studies of Levocetirizine and Desloratadine for the Symptoms of Allergic Rhinitis 59
La diagnostica delle malattie autoimmuni 59
The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU 59
EUFOREA consensus on biologics for CRSwNP with or without asthma 58
A review of the use of fluticasone furoate since its launch 58
GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe 58
Year in review: Allergen immunotherapy 58
Quality-of-life issues in survivors to anaphylactic reactions to drugs 58
Minimal important difference of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) 58
Clinical outcomes related to molecular allergy diagnosis 57
Intercellular adhesion molecules: Clinical Perspectives 57
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs 57
The adhesion molecules of allergic inflammation: recent insights into their functional roles 57
Inhibitory effect of an antibody against alpha 1-acid glycoprotein (alpha 1-AGP) on autologous mixed lymphocyte reaction and anti-T3 T-lymphocyte activation 57
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update 57
Cross-cultural adaptation and validation of the RhinAsthma Patient Perspective (RAPP) in Spanish 57
Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy 57
[Anti-leukotriene agents: rationale for and prospects of use] 57
A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis 57
[Immunotherapy in Latin America. From the past to the future] 57
Circulating T cell subsets in euthyroid Graves' disease 57
The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey 57
Cross-cultural adaptation of the Brazilian-Portuguese version of the chronic urticaria quality-of-life questionnaire - CU-Q2oL 57
Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study 57
Inhaled corticosteroids safety and adverse effects in patients with asthma 56
Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more 56
Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites 56
«ICAM-1/ CD54 expression on conjunctival epithelium during pollen season» 56
Responders and nonresponders to pharmacotherapy and allergen immunotherapy 56
Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce 56
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. 55
Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update 55
Totale 7.595
Salva come PNG Salva come JPEG
Categoria #
all - tutte 322.277
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 322.277
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218.123 0 0 0 0 0 2.500 1.316 572 2.071 696 14 954
2021/20223.078 117 7 51 783 15 17 131 612 304 295 682 64
2022/20234.270 1.621 85 827 139 101 86 19 93 282 776 219 22
2023/20243.405 169 387 772 31 32 141 119 117 51 34 640 912
2024/20255.989 79 34 38 53 56 788 212 382 704 1.956 749 938
2025/202612.594 2.652 1.457 2.597 5.022 662 204 0 0 0 0 0 0
Totale 38.310